Accent Capital Management’s AstraZeneca AZN Stock Holding History

Accent Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$178K	Buy	905 +405	+81%	+$78.1K	0.09%	49
2025 Q4	$91.9K	Hold	500	–	–	0.04%	66
2025 Q3	$76.7K	Hold	500	–	–	0.03%	75
2025 Q2	$69.9K	Hold	500	–	–	0.03%	82
2025 Q1	$73.5K	Hold	500	–	–	0.04%	81
2024 Q4	$65.5K	Sell	500 -121	-19%	-$16.9K	0.04%	72
2024 Q3	$96.7K	Hold	621	–	–	0.06%	75
2024 Q2	$96.8K	Buy	621 +63	+11%	+$9.48K	0.06%	74
2024 Q1	$75.5K	Hold	558	–	–	0.07%	63
2023 Q4	$75.1K	Buy	+558	New	+$72.5K	0.06%	80

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Accent Capital Management's AZN Position: Q1 2026 in Review

Accent Capital Management increased its AstraZeneca (AZN) stake by 81% in Q1 2026, buying an estimated $78.1K and bringing the position to 905 shares worth $178K. The position accounts for 0.09% of the portfolio, ranked #49.

Accent Capital Management first reported a position in AZN in Q4 2023 and has held it in 10 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Accent Capital Management held 905 shares of AstraZeneca worth $178K as of Q1 2026.
Accent Capital Management bought 405 AstraZeneca shares in Q1 2026, an estimated $78.1K.
AstraZeneca made up 0.09% of Accent Capital Management's portfolio in Q1 2026, its #49 holding.
Accent Capital Management first reported a position in AstraZeneca in Q4 2023 and has held it in 10 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.